Keyword: CEPI

CureVac is working on a printer to quickly create mRNA vaccine candidates against known pathogens and unknown diseases.

Here is some other vaccine news of note for the week.

Here is some other vaccine news of note for the week.

Here is some other vaccine news of note for the week.

With the help of BioNTech and CEPI's $8.4 million, Imperial College London will work on a self-amplifying RNA vaccine platform.

There aren’t any vaccines against the painful viral infection chikungunya, but with new phase 2 results, Themis is one step closer to changing that.

In its latest development deal, the outbreak readiness group CEPI has awarded J&J and Oxford University $14.6 million for work on a MERS vaccine.

Right on the heels of last week's deal in Lassa fever, CEPI has awarded IDT Biologika up to $36 million for MERS research.

Profectus’ Lassa candidate is based on its VesiculoVax vaccine delivery platform, which uses vesicular stomatitis virus as vector.

Inovio's South Korean partner GeneOne plans to start a phase 1/2 study in South Korea in the third quarter.